Dupixent’s Deadly Risks
We’re actively investigating cases where Dupixent (dupilumab) may be linked to Cutaneous T-Cell Lymphoma (CTCL)— a group of rare blood cancers that affects the largest organ in your body — your skin.
One study found that people using Dupixent to treat eczema may be up to four times more likely to develop CTCL compared to those who didn’t use the drug. Experts believe this may happen because Dupixent works by calming the immune system and reducing inflammation—while that helps with eczema symptoms, it may also hide early warning signs of lymphoma. As a result, the cancer could go unnoticed and continue to grow before it’s diagnosed.
If you or a loved one developed CTCL after using Dupixent, you may be entitled to compensation. Patients deserve transparency, accountability, and support—not silence. We are here to help you seek justice and hold the responsible parties accountable.
Understanding Cutaneous T-Cell Lymphoma (CTCL)
CTCL is a rare type of non-Hodgkin lymphoma that affects the skin. It originates in T-cells—immune cells that normally fight infection—and presents as persistent skin rashes or patches. The two most common subtypes are:
- Mycosis Fungoides: Begins as red, scaly patches that resemble eczema or psoriasis. It can progress to tumors or spread internally.
- Sézary Syndrome: A more aggressive form that causes widespread skin redness, swollen lymph nodes, and cancerous cells in the blood.
Dupixent and CTCL: What’s the Connection?
Some patients prescribed Dupixent for eczema later received a diagnosis of CTCL. In several reported cases, symptoms worsened after starting Dupixent, leading to further testing and discovery of underlying lymphoma.
While researchers have not confirmed a direct causal link, medical experts believe Dupixent may:
- Mask early signs of lymphoma
- Delay accurate diagnosis
- Accelerate disease progression in undetected cases
Symptoms to Watch for While Using Dupixent
If you’re currently using Dupixent, monitor your skin and overall health carefully. Warning signs may include:
- Skin patches that don’t heal or worsen over time
- Persistent redness or itching that intensifies
- Swollen lymph nodes
- Unexplained fatigue or weakness
- Skin changes that no longer respond to treatment
If you notice any of these symptoms, consult your healthcare provider immediately. A skin biopsy or blood test may be necessary to rule out CTCL.
FDA Monitoring CTCL Reports
According to recent reports, the FDA is actively monitoring cases of CTCL in patients who were treated with Dupixent. These cases have raised concerns that the drug may:
- Unmask pre-existing CTCL by suppressing inflammation and delaying diagnosis
- Accelerate disease progression in patients with undetected lymphoma
The FDA has not yet issued a formal warning or label update, but it is evaluating whether regulatory action is needed—including the possibility of updating Dupixent’s safety labeling.
